A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Phase 1/2 Terminated 49 enrolled Alnylam Pharmaceuticals

RandomizedSequentialTriple-blindTreatment

Summary

To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.

Timeline

Start: 2023-03-10
Primary completion: 2025-04-03
Completion: 2025-04-03

Outcome

Outcome not reported

Stopped (Business): “Business reasons (not safety related)”

Publications

Badri P, Kolachana K, Duong A, Lasko M, Nandi T, Mehrotra N, Robbie GJ. Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules. Clin Pharmacokinet. 2026 Feb;65(2):293-311. doi: 10.1007/s40262-025-01606-0. Epub 2025 Dec 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALN-KHK	Unknown	—	Subcutaneous